Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01146925 · ClinicalTrials.gov registry record · Phase 2
Deferiprone for the Prevention of Contrast-Induced Acute Kidney Injury
A Phase 2 study of Contrast Induced Acute Kidney Injury, sponsored by CorMedix.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 8
- Study locations
NCT01146925: Completed Phase 2 study of Contrast Induced Acute Kidney Injury, sponsored by CorMedix.
NCT01146925 is a Phase 2 study of Contrast Induced Acute Kidney Injury that has completed, run by CorMedix. The registered enrollment target is 60 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower). The trial reports 8 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01146925, a Phase 2 study of Contrast Induced Acute Kidney Injury, has completed, sponsored by CorMedix.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 8
- Study locations
Study Summary
The primary objective of this trial is to assess the impact of CRMD-001 on markers of contrast-induced acute kidney injury (AKI) in high-risk patients with chronic kidney disease (CKD) undergoing coronary angiography and PCI.
Primary Outcome
Mean paired change in a panel of acute kidney injury (AKI) biomarkers (urinary NGAL, LFABP, interleukin-18 (IL-18), kidney injury molecule-1 (KIM-1), urinary alpha GST (proximal tubular injury), Pi GST (distal tubular injury) and cystatin C; serum cystatin C) from baseline (Day 1) to peak in the deferiprone and placebo treatment groups, within 192 hours of contrast exposure
Conditions Studied
Interventions
- DRUG Placebo
- DRUG CRMD-001-Deferiprone
Study Locations (8)
Michigan
- St. John Hospital and Medical Center - Detroit
- Cardiac and Vascular Research Center of Northern Michigan - Petoskey
- Providence Hospital - Southfield
Ohio
- Ohio Health Research Institute - Columbus
- Cardiovascular Catheterization Labs at Fairfield - Fairfield
- St. Vincent Mercy Medical Center - Toledo
Indiana
- The Care Group, St. Vincent's Hospital - Indianapolis
Oklahoma
- Oklahoma Cardiovascular Research Group - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2010-06 |
| Est. Completion | 2011-06 |
| Phase | Phase 2 |
What the finished NCT01146925 record still lists
NCT01146925 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower).
The record links to 1 condition, with Contrast Induced Acute Kidney Injury appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01146925 lists 8 locations in 4 states (Michigan, Ohio, Indiana).
Frequently Asked Questions
What is clinical trial NCT01146925 about?
NCT01146925 is a clinical study titled "Deferiprone for the Prevention of Contrast-Induced Acute Kidney Injury". The primary objective of this trial is to assess the impact of CRMD-001 on markers of contrast-induced acute kidney injury (AKI) in high-risk patients with chronic kidney disease (CKD) undergoing coronary angiography and PCI.
What is the current status of trial NCT01146925?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2010-06. Estimated completion is 2011-06.
What conditions does trial NCT01146925 study?
This clinical trial studies the following conditions: Contrast Induced Acute Kidney Injury.
What interventions are being tested in trial NCT01146925?
The interventions under investigation include: Placebo (DRUG), CRMD-001-Deferiprone (DRUG).
Who is sponsoring clinical trial NCT01146925?
This trial is sponsored by CorMedix, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01146925 being conducted?
This trial has 8 study locations across Indiana, Michigan, Ohio, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Contrast Induced Acute Kidney Injury
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01146925's enrollment target sits among peer trials
60 1027th of 2000 higher than 868 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia